Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Drug-drug Interaction,SHR3680 1Advanced Solid Malignancies 1

Interventions

pembrolizumab 282Carboplatin 217Cisplatin 147Gemcitabine 146Paclitaxel 142Bevacizumab 116Pemetrexed 114Docetaxel 101Oxaliplatin 79durvalumab 78Dexamethasone 77Fluorouracil 76atezolizumab 75Nivolumab 75Cyclophosphamide 74130-nm albumin-bound paclitaxel 71Fulvestrant 70Capecitabine 64Cetuximab 63Injections 62Leucovorin 60Rituximab 55fludarabine 50Lenalidomide 50venetoclax 44Prednisone 43Irinotecan 42Letrozole 40enzalutamide 39tislelizumab 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Digoxin × 90 days × Clear all
NCT04621669 2026-06-05

Drug-durg Interaction of SHR3680 With Digoxin, Rosuvastatin Calcium and Metformin Hydrochloride

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
36 enrolled

Drug-drug Interaction,SHR3680

NCT06899061 2026-03-27

Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib

AstraZeneca

Phase 1 Active not recruiting
41 enrolled

Advanced Solid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡